Fenofibrate

Caffeine Naproxen, triclosan and clofibric acid. Other pharmaceuticals covered in analysis chlorophene, fluoxetine, ibuprofen ; Caffeine, diclofenac, ibuprofen, ketoprofen, naproxen, fenoprofen and gemfibrozil removed over six months. Carbamazepine and primidone not removed after several years. Other pharmaceuticals meclofenamic acid, tolfenamic acid, clofibric acid, fenofibrate, pentoxifylline, fenopropen ; not detected.

P-T-627 CORRECTION HAEMOSTASIOLOGIC AND RHEOLOGIC DISTURBANCES AT THE PATIENTS WITH ISCHEMIC HEART AND BRAIN DESIASES BY MEANS OF COMBINATION OF PHARMACOLOGICAL DRUGS AND EXTRACORPOREAL AUTOBLOOD-MAGNET-THERAPY N. G. Kruchinsky * BY ; , A. I. Teplyakov, D. K. Zubovsky THE EFFECT OF AGE AND GENDER ON THE PHARMACOLOGY AND SAFETY OF THE ORAL, DIRECT FACTOR XA INHIBITOR RIVAROXABAN D. Kubitza * DE ; , M. Becka, W. Mueck, M. Zuehlsdorf ANTIPLATELET AND ANTITHROMBOTIC ACTIVITY OF NP-313, 2-ACETYLAMINO-3CHLORO-1, 4-NAPHTHOQUINONE, A NOVEL CPLA2 AND CYTOSOLIC CA 2 + MOBILIZATION INHIBITOR H. L. Kuo * TW ; , J. C. Lien, S. C. Kuo, C. H. Chung, C. H. Chang, T. F. Huang ANTIPLATELET ACTIVITY OF FENOFIBRATE, A PPARALPHA AGONIST, WAS MEDIATED BY BLOCKING OF CYTOSOLIC CALCIUM MOBILIZATION AND THROMBOXANE A2 RECEPTOR J. Lee * KR ; , Y. Jin, Y. Lim, J. Yu, J. Lee, M. Tudev, J. Im, E. Park, T. Kim, M. Lee, Y. Yun EFFECTS AND MECHANISMS OF BUYANG HUANWU DECOCTION ON THE CELL VIABILITY AND TF EXPRESSION INDUCED BY ANGII IN ENDOTHELIAL CELLS J. L. Li * Xiong, W. H. Zhu SEROTONERGIC MECHANISMS IN HAEMOSTASIS: A CONNECTION BETWEEN MAJOR DEPRESSION AND THROMBOTIC RISK I. Lopez-Vilchez * ES ; , M. Serra, A. Alonso, F. Navalon, R. Hernandez, E. Gomez, C. Gasto, G. Escolar, A. M. Galan. Aippg largest medical community of the web - aippg ™ plab section ielts tips mrcp mock tests all india preparation tips, add yours as well congenital adrenal hyperplasia forum home » mrcp forum author message posted: mon jun 18, 2007 post subject: congenital adrenal hyperplasia regarding congenital adrenal hyperplasia cah ; , which of the following is false. Data from the first trial of long-term fibrate treatment do not warrant a recommendation for increased fenofibrate use in patients with diabetes, authors of a commentary on the study argue. The study, published early online on The Lancet website thelancet ; , randomised 9, 795 patients aged 5075 years with type 2 diabetes to receive either placebo or micronised fenofibrate 200mg daily. Although fenofibrate did not reduce the risk of a composite of coronary heart disease death and non-fatal myocardial infarction, it did reduce the total number of cardiovascular events relative risk 0.89; 95 per cent confidence interval 0.800.99, P 0.035 ; . This reduction was principally the result of a 24 per cent reduction in non-fatal MI 0.76; 0.620.94, P 0.010 ; . However, the authors of an accompanying commentary ibid ; argue that large differences in the results for different subgroups in the trial mean that the study is unable to provide clear answers about the efficacy and safety of fenofibrate. For instance, the 11 per cent reduction in cardiovascular events was made up of a per cent reduction for patients without previous cardiovascular disease and a non-significant 8 per cent increase for patients with previous cardiovascular disease. "The results from this well executed trial do not warrant a recommendation for increased fenofibrate use in patients with diabetes, nor do they provide convincing evidence of the benefit of fenofibrate therapy in patients already at target serum lowdensity lipoprotein cholesterol, " the commentators say and tricor. The revised consensus guidelines were issued by none less than the American Heart Association and were drawn up by a government panel of experts in the field, convened by the NIH's own National Heart, Lung, and Blood Institute. The new rules, if sustained, would lower serum cholesterol targets to a point where 7 million more Americans would be encouraged to start taking the cholesterol lowering medications of Pfizer, Merck, BMS and AstraZeneca. At $1, 500 or so a year and 20-30% margins, we're talking an additional $2-3 billion a year in profits--with little more than the stroke of a pen. ; New York Newsday first reported -- continued on next page.

Fenofibrate online Femilon apri cyclessa desogen kariva mircette ortho-cept fenolip fenofibrate tricor fenoxene dibenzyline phenoxybenzamine fensaide diclofenac voltaren fertomid clomiphene clomid milophene fibral fenofibrate lofibra tricor finasteride fincar finasteride proscar propecia finepecia finasteride proscar propecia finpecia finasteride proscar propecia flagyl metronidazole flagyl - metronidazole flameril voltaren diclofenac flixonase flonase flixonase fluticasone flixotide flovent flonase fluxotide fluticasone propionate cfc inhaler flixotide flovent floease fluticasone flixotide flovent flohale rotacap fluticasone flixotide flovent flomax flomax mr tamsulosin hydrochloride flomaxtra a b c index prescriptions in alphabetical order and flavoxate. After taken this medicine, you may experience some dizzy, so do not run any machine or do not drive that requiring full mental wakefulness. Elan corporation pharmaceutical company 2007 2006 2005 prialt media kit click here for printable version 6 july 2006 elan signs license agreement with abbott for elan's proprietary nanocrystal technology; to develop a single fixed-dose combination of tricor and crestor for high cholesterol patients dublin, ireland- business wire ; -july 6, 2006-elan corporation, plc nyse: eln ; today announced that it has entered into a license agreement with abbott pharmaceutical pr ltd nyse: abt ; in which abbott has been granted us rights, in a partnership with astrazeneca pharmaceuticals, lp, to utilize elan's proprietary nanocrystal technology to develop and commercialize a single fixed-dose combination product containing the active pharmaceutical ingredients in abbott's tricor 145 fenofibrate ; and astrazeneca's crestor rosuvastatin calcium ; products and urispas.

Fenofibrate cure To improve digestion and protect against the trots, take three or four tablets of hcl with each meal. School of Pharmacy, Temple University, Philadelphia, PA provide sink conditions.1, 7, 8 Absence of sink conditions may result in unpredictable release kinetics and suppression of release profiles. Generation of dissolution data under nonsink condition can easily overweigh the role of formulation changes in the selection of candidate formulation see Figure 1 ; . Different techniques eg, addition of organic solvents to aqueous medium or use of 2-phase solvent system ; , 2 use of large dissolution volume, removal of dissolved drug, pH changes, and addition of surfactants or their combinations have been employed by scientists to improve solubility and ensure sink conditions.4, 9 Of note, any modification applied should be relevant to real GI conditions. Among aforementioned approaches, pH modification and surfactant addition appear to be the simplest and can be tailored to resemble GI fluid environment. Finally, construction of in vitro-in vivo correlation provides the most valuable data for selection of the most appropriate dissolution method and testing conditions that can be prognostic of in-vivo dissolution. This report describes dissolution quality assessments, in the evaluation of the rate of dissolution for 2 low solubility drugs, glipizide and fenofibrate. The influence of formulation, sink conditions, surfactant type, and medium pH on their dissolution behavior and discriminatory effect of dissolution testing is also presented. Glipizide is an oral antidiabetic agent and fenofibrate is a dyslipidaemic drug. Dissolution of immediate release commercial fenofibrate Tricor 54-mg and 160-mg tablets ; and controlled release 10-mg glipizide tablets developed by the authors10 were studied and flunarizine. 1 O'Leary F, Hanson J, Bradbury R, Thanakrishman G. Fatal leptospirosis presenting as musculoskeletal chest pain. Med J Aust 2004; 180: 29-31. Guidugli F, Castro AA, Atallah AN. Antibiotics for leptospirosis Cochrane review ; . In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd. 3 Takfuji E, Kirkpatrick J, Miller R, et al. An efficiency trial of doxycyline chemoprophylaxis against leptospirosis. N Engl J Med 1984; 310: 497-500. Kucers A, Crow S, Grayson M, Hoy J. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Boston: Butterworth-Heinemann, 1997. 5 Friedland J, Warral D. The Jarisch-Herxheimer reaction in leptospirosis: possible pathogenesis and review. Rev Infect Dis 1991; 13: 207-210. Katz A, Ansdell V, Effler P, et al. Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii 1974 1998. Clin Infect Dis 2001; 33: 1834-1841. Therapeutic guidelines. Antibiotic. Version 12. Mel bourne: Therapeutic Guidelines, 2003.

Mental Health CRITERIA FOR MAJOR DEPRESSION At least one episode of dysphoric mood and or loss of interest or pleasure in all or almost all usual activities and pastimes, sufficient to disturb normal function or to cause distress. Dysphoric mood is characterized by depression, sadness, hopelessness and irritability. The mood disturbance must be prominent, pervasive and relatively persistent. At least five of the following symptoms present nearly every day for a period of at least 2 weeks: Change in appetite or weight increase or decrease ; Insomnia at any stage of sleep but especially in morning Increased sleeping hypersomnia ; Psychomotor agitation inability to sit still, pacing, hand-wringing ; or retardation slowed speech, long pauses before answering, low or monotonous speech, slowed body movements, decreased amount of speech ; Loss of interest or pleasure in sex, decrease in libido Loss of energy Fatigue Feelings of worthlessness, self-reproach, or excessive or inappropriate guilt may be of delusional nature and proportions ; Complaints or evidence of diminished ability to think or concentrate slowed thinking, indecisiveness ; and recurrent thoughts of death, suicidal ideation, wishes to be dead or suicide attempt Absence of bizarre behavior and inappropriate mood mood inconsistent with content of delusions or hallucinations ; . Not due to or superimposed on schizophrenia, paranoid disorders, organic mental disorder, uncomplicated bereavement, infectious disease, hypothyroidism, substances such as reserpine, alcohol dependence or other chronic mental disorder. Severity and duration must be sufficient to warrant label of "major" depression, as distinct from more chronic, less severe, periodic mood disorders see "Dysthymic Disorder Depressive Neuro sis ; , " below, this section and flupenthixol!

ANTILIPEMICS Guidelines for the use of antilipemics in various patient populations are available at: : nhlbi.nih.gov Antilipemic Combinations ezetimibe simvastatin Bile Acid Resins cholestyramine colesevelam colestipol Cholesterol Absorption Inhibitors ezetimibe Fibrates fenofibrate fenofibrate fenofibrate, micronized gemfibrozil HMG-CoA Reductase Inhibitors atorvastatin fluvastatin fluvastatin ext-rel NF lovastatin lovastatin ext-rel pravastatin rosuvastatin simvastatin VYTORIN. In persons with type 2 diabetes, treatment with micronized fenofibrate reduces angiographic CAD progression. Results were similar in men and women, and were consistent with or without a history of coronary intervention and at lipid levels often con and fosinopril and fenofibrate. Co-proxamol is very toxic in overdose. The odds of dying after a coproxamol overdose are 28 times greater than after a paracetamol overdose. Yet co-proxamol contains a subtherapeutic dose of paracetamol. CSM advice The CSM has advised that no new patients should be started on co-proxamol. Patients currently taking co-proxamol should be moved to alternative pain control at their next routine appointment. The CSM asks health professionals to give the following advice to patients: never exceed the recommended dose never consume alcohol while taking a course of co-proxamol Dispose of any unused supplies through a pharmacist ; as soon as possible after completing treatment.
Doral.17 Doryx.16 doxazosin mesylate .8 doxepin HCl.6 doxycycline hyclate capsule.4 doxycycline hyclate tablet .4 doxycycline monohydrate .4 Duoneb.3 Duricef.16 Dynacin.16 DynaCirc CR.17 DynaCirc.17 E Effexor.7 Effexor XR .7 Elavil .17 enalapril maleate.8 enalapril maleate hydrochlorothiazide.8 EryPed.16 erythromycin base.4 erythromycin ethylsuccinate .4 erythromycin ethylsuccinate sulfisoxazole acetyl .4 erythromycin stearate.4 Esclim Patch.19 estazolam .6 Estinyl.19 Estrace.19 Estraderm Patch .13 estradiol patch .12 estradiol tablet.12 Estratab.19 Estratest.13 Estratest H.S.13 Estring Vaginal Ring.13 estropipate .12 Estrostep Fe.19 ethynodiol d-ethinyl estradiol.12 etodolac.14 etodolac tablet, sustained release 24 hr .14 Evista.13 F Factive .16 famotidine.14 Fast Take Test Strips .11 Femhrt .19 Femring .19 fenofibrate, micronized .8 Flonase.3 Flovent Inhaler.3 Flovent Rotadisk.3 Floxin .16 fluconazole .4 flunisolide.2 fluoxetine HCl .6 fluphenazine HCl .6 flurazepam HCl.6 flurbiprofen.14 fluvoxamine maleate.6 Foradil.3 Fosamax Solution.13 Fosamax Tablet.13 fosinopril sodium.8 fosinopril hydrochlorothiazide.8 Fulvicin P G.16 Fulvicin U F .16 Fungizone.5 and geodon.

CHD risk were observed in those with lower intakes of saturated fat or trans fat or higher intakes of vegetables fruits. Conclusions Among postmenopausal women, a low-fat dietary pattern did not result in a statistically significant reduction in invasive breast cancer, invasive colorectal cancer or risk of CHD, stroke or CVD over an 8.1-year average follow-up period. There were some nonsignificant trends suggesting reduced risk of invasive breast cancer or CVD associated with a low-fat dietary pattern suggesting that more focused diet and lifestyle interventions may be needed. Lipidil tm ; ez, a nano-crystallized form of fenofibrate, was recently launched in canada. Spread from the primary site 22 ; . We found that fenofibrate inhibits both Erk1 2 and Akt phosphorylation in a PPARadependent fashion, although only the latter event is functionally linked with fenofibrate-mediated growth repression and inhibition of migration. Both phosphatidylinositol 3-kinase Akt and mitogen-activated protein kinase Erk1 2 pathways play important roles in normal and malignant cell migration 34 37 ; . PPARs have been reported to interfere with both these pathways. PPARg and PPARa ligands, including fenofibrate, inhibit vascular endothelial growth factor and basic fibroblast growth factor induced endothelial cell migration, which is accompanied by a decrease in Akt phosphorylation 38, 39 ; . In contrast, some other authors report a rapid but transient increase of Erk1 2 and Akt phosphorylation caused by PPARa and PPARg ligands in cell culture conditions 40 42 ; . However, in these studies, changes in the phosphorylation status were detected shortly 10-30 minutes ; after the treatment and therefore cannot be ascribed to canonical activity of PPARs as transcription factors. Such rapid, ``nongenomic'' effects are most likely PPAR independent 42, 43 ; . In our case, fenofibrate. STATINS AND FIBRATES The possibility of increased myotoxicity with the use of statins in combination with fibric acid therapy is an additional important clinical consideration. With ATP III's lowered cutpoint for triglycerides from 200 to 150 mg dL ; and the elevation of the normal HDL cholesterol level from 35 to 40 mg dL ; , clinicians are more likely to use statins in combination with fibric acid derivatives and niacin to achieve these goals. Gemfibrozil interactions are well described, 38, 39 with increases in muscle toxicity of 1% to 5%.31, 39-41 In a recent trial, 42 the combination of simvastatin and gemfibrozil resulted in simvastatin acid concentrations that were almost 3-fold higher. A similar result was reported with lovastatin and gemfibrozil, but bezafibrate marketed in Europe ; had no effect on lovastatin concentrations, which suggests a difference in effect among fibric acid derivatives.43 This class effect is also suggested by reports that fenofibraate does not affect pravastatin concentrations.44 A reasonable approach in the use of combination therapy might be to lower the statin dose and add a fibrate that is not likely to increase statin plasma levels. The patient should also be observed closely for signs and symptoms of muscle toxicity. RECOMMENDATIONS FOR CK MONITORING According to the ACC AHA clinical advisory22 and other sources, 45 CK monitoring is not required in patients taking statins. Because the onset of myopathy is frequently abrupt, unlike hepatotoxicity, monitoring is not deemed beneficial. On the other hand, many experts and the ATP III guidelines recommend that a baseline CK reading be obtained prior to starting statin therapy, since asymptomatic CK elevations are sometimes present. Certainly, if myopathy exists prior to statin treatVol. 3, No. 10.
These medications are not a covered benefit under the Medicare Modernization Act. Therefore, Highmark will not provide coverage for drugs within these classes. Other entities may pay for these medications for the beneficiary self-pay, PACE ; . However, any claims for these agents will not be captured within the Highmark claim database. Thus these medications, although problematic within the elderly, may prove to be difficult to intervene upon due to a lack of administrative data. They are included for completeness and tricor.

TABLE 40 Studies including IgG TTG antibody tests Author, year Lock et al., 1999169 Troncone et al., 1999185 Details of method test kit, substrate, manufacturer ; Method by Dieterich et al., 1997 In-house Thresholds for positivity Not stated 97th percentile of control group. To treat mild ulcers, the leg should be gently washed with cotton gauze soaked in mild soap or a solution of one tablespoon of household bleach to one gallon of water. He concluded that the only known alternative to preserve randall's sight which would avoid the significant risks of surgery is to include marijuana as part of randall's prescribed medical regimen.

Scenario 1 I guess the only question is what was aspirated - is this an abscess rather than cellulitis? If so then it is Category 5 The scenario doesn't specify what material the aspirate was from, if it had been from a fluid filled lesion, it could have been an abscess. We could have clarified in the scenarios where the aspirate was taken from.While cellulitis is typically not cultured, post vaccination cellulitis deserves special attention, because it is a very rare event and may involve technical or programmatic errors. Scott explained how they aspirate culture material from a cellulitis subcutaneous tissue ; , and it was suggested to put this technique into the document. However, we agreed not to include this since we are not providing clinical management guidance. Scenario 2 should be reported as an abscess; If we consider note 8 to the case definition. However, considering guideline 25, it could be both, cellulitis and abscess. Exclusion criteria may be listed separately; This is a problem with the definition since some would call it both cellulitis and abscess as in 25 ; but to me the fluctuance precludes the diagnosis of cellulitis - this is an area of ambiguity. Before the lesion became fluctuant it could and should be classified as level 1. So classification depends on the timing that an area was examined. Abscess having a higher hierarchy solves this problem. Cellulitis can develops into an abscess. Scenario 3 According to the case definition of cellulitis, I consider the antibiotic treatment equal to a physician health care provider diagnosis: However, lab confirmation is lacking. Therefore level 2.; Presuming of course that the reason for the antibiotics is the diagnosis of cellulitis 4 In some countries where antibiotics can be prescribed by any health care providers not necessary by physicians In countries where the health system can assure that antibiotics are sold only under medical prescription , it might be considered a level 2. 5Note that in many countries, an antibiotic could be obtained without a perscription or interactionn with health care worker. Treatment is not a criterion in deciding on a level. If we had known who had reported the case, the confusion would have been okay, and we typically know who reported an event. We also had made the assumption that a physician reported the case, because antibiotics were given. We realize that one cannot make that assumption and information non who reports is important. It is a problem of the case scenario other than the case definition. Scenario 4 6 Rapid resolution!; Should be considered as erythema and induration at injection site. By the definition, "rapid resolution" is an exclusion criteria and the foot note implies that "rapid" is in 2 days or less This is okay. The reasons given are appropriate for classifying the event as not a case. Scenario 5 7 If understand the def it's a 3 but in a passive notification system I'd classify it as an important local reaction 8 Information about several inclusion criteria is missing. Probably level 3, but additional sign needs to be cited. At least one more of the cellulitis symptoms is needed since it has been reported by the parents. 9 According to the definition, it might be classified as level 3, second possibility. However, I would not agree to this. This case is difficult to classify because time of resolving is about a week but appeared to be spontaneous. In note#7 for case definition said : usually cellulitis at injection site are usually resolving within 2 days and not resolve spontaneously. Need some clarification. We deleted the `second option of level 3' from the definition document, which would resolve confusion with this scenarios. We previously discussed that we cannot give further guidance on the time frame of resolution. Too little is known.
Glutamate and glutamate receptors are located in areas of the brain, spinal cord and periphery that are involved in pain sensation and transmission. Glutamate acts at several types of receptors, including ionotropic directly coupled to ion channels ; and metabotropic directly coupled to intracellular second messengers ; . Ionotropic receptors include those selectively activated by N-methyl-D-aspartate, acid and kainate. Metabotropic glutamate receptors are classified into 3 groups based on sequence homology, signal transduction mechanisms and receptor pharmacology. Glutamate also interacts with the opioid system, and intrathecal or systemic coadministration of glutamate receptor antagonists with opioids may enhance analgesia while reducing the development of opioid tolerance and dependence. Exhausted and read out. Risk of rhabdomyolysis similar to that observed with less potent agents.6-8, 31 In fact, during a recent intensive review of safety data for rosuvastatin, the Food and Drug Administration concluded that rhabdomyolysis is an extremely rare event among users of all marketed statins, with an estimated incidence of 1 in 10, 000 patients.29 PROVIDING ADEQUATE LIPID MANAGEMENT In clinical practice, less than half of patients achieve desired LDL-C levels during statin therapy.32 Possible reasons for the inadequate lipid management include inadequate dosages of the drugs, failure to implement treatment guidelines, adverse events, and noncompliance. To help patients reach the recommended goals, the clinician has 3 options: prescribe high doses of one of the older statins, combine a moderate- or high-dose statin with an agent that acts in a complementary fashion, or prescribe one of the newer, more potent statins. Current recommendations are to begin statin therapy at the lowest dose and titrate upward if lipid goals are not met.32 On average, doubling the statin dose reduces LDL-C levels by an additional 6%. Thus, dose titration is a reasonable choice for patients who are within approximately 10% of goal. However, in clinical practice, most patients who begin treatment with a statin remain at the initial dose.32 Moreover, dose titration to the maximum recommended by the manufacturer increases costs, the need for follow-up, and the risk of adverse events. Finally, it is not always effective, particularly with a less potent agent or in a high-risk patient who requires a substantial reduction in LDL-C levels. Combination therapy is an option for patients with mixed dyslipidemia. The fibrates are effective at lowering triglycerides when coadministered with a statin. However, the Food and Drug Administration advises caution with statin-fibrate therapy because of the increased risk of myopathy.19 Of the fibrates, gemfibrozil appears to have the greatest risk of drug-drug interaction with a statin, whereas femofibrate has a much lower potential risk.19 For patients who have an elevated LDL-C level and a low level of high-density lipoprotein cholesterol, niacin-statin therapy is considered a reasonable choice. The extended-release formulation of niacin approved by the Food and Drug Administration shows no significant hepatotoxicity.19, 29 The specific cholesterol absorption inhibitor ezetimibe and the bile acidbinding polymer colesevelam may be combined with statins for patients who have not reached target LDL-C levels during statin monotherapy titrated to the maximum dose.32 Current data suggest that the addition of ezetimibe to a statin regimen may lower LDL-C levels by an additional 12% to 14% with no increased safety risk, other than increased monitoring of liver enzyme levels.19.
PLYMOUTH, Mich ohnson Controls recently was selected as "Corporation of the Year" for 2006 by the Central and South Texas Minority Business Council CSTMBC ; for its outstanding achievements in developing diverse supplier companies. Representatives from CSTMBC presented Johnson Controls with the top honors at the group's 2006 Awards Banquet earlier this month. Kenneth Gardner, diversity business development manager for the Automotive Experience business of Johnson Controls, accepted the award. The event, attended by company purchased approximately $1.004 billion in goods and services from diverse firms, making it a member of the "Billion Dollar Roundtable" that includes just 12 companies that spend $1 billion annually with diverse suppliers. "Embracing diversity, and the positive results that it generates, is an important part of our company's corporate mission, values and business strategy, " said Keith Wandell, president and chief operating officer of Johnson Controls. "We are pleased to be recognized by the CSTMBC for our minority supplier development activities in Texas." The Corporation of the Year recognition earned by Johnson Controls was for companies that actively include certified minority suppliers in their procurement opportunities; assist in the development of minority suppliers; and promote supplier diversity and business development within their corporation and to their vendors and other businesses and organizations!